KLK3 and pachyonychia congenita: It may potentially distinguish patients with biologically indolent PC (i.e., amenable to reduce the duration of androgen deprivation therapy (ADT), when prescribed, but not sufficient to guide postoperative radiotherapy (RT) omission in case of post-prostatectomy PSA persistence even after low-to-intermediate GC risk reclassification) from aggressive disease deserving treatment intensification [73,74].